New Britain, CTNCT06578195Now EnrollingIRB Ready

Amyotrophic Lateral Sclerosis Clinical Trial in New Britain, CT

Access cutting-edge amyotrophic lateral sclerosis treatment through this clinical trial at a research site in New Britain. Study-provided care at no cost to qualified participants.

Sponsored by St. Joseph's Hospital and Medical Center, Phoenix

Quick Self-Assessment

See if you qualify for this New Britain location

Preparing your pre-screening questions…

Expert Care in New Britain

Access amyotrophic lateral sclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related amyotrophic lateral sclerosis treatment provided free

Apply for This New Britain Location

Check if you qualify for this amyotrophic lateral sclerosis clinical trial in New Britain, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Britain

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Britain site if eligible
  4. 4Begin participation

About This Amyotrophic Lateral Sclerosis Study in New Britain

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix

Who Can Participate

Inclusion Criteria

for ALS participants:
Age 18 years or older
Capable of providing informed consent
Willing to follow study procedures
Diagnosis of ALS by a physician
Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient) Inclusion Criteria for control participants:
Age 18 years or older
Capable of providing informed consent
Willing to follow study procedures
No diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS)
No history of familial ALS/Frontotemporal Dementia (FTD) in a close family member\*\
unless the participant has previously tested negative for the known causative ALS genes. Participants with a family history of singleton ALS are permitted to enroll.
Defined by the presence of a known ALS causative gene such as C9orf72 in a family member or a family history suggestive of an inherited ALS/FTD syndrome defined by two family members with a history of ALS and/or FTD.
Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)

Exclusion Criteria

for all participants:
Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression \<= 90 days of screening, that would interfere with the study procedure, according to Investigator's judgement.
Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment. Exclusion Criteria for participants undergoing optional Lumbar Puncture
Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
Allergy to Lidocaine or other local anesthetic agents.
Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
Current pregnancy based on participant self-report
Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Britain?

Yes, this clinical trial (NCT06578195) has an active research site in New Britain, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Amyotrophic Lateral Sclerosis Treatment Options in New Britain, CT

If you're searching for amyotrophic lateral sclerosis treatment options in New Britain, CT, this clinical trial (NCT06578195) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Britain research site is actively enrolling participants for this clinical trial. You'll receive care from experienced amyotrophic lateral sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all amyotrophic lateral sclerosis clinical trials near you to find additional studies recruiting in your area.

More ALS Trials in New Britain, CT

See all als clinical trials recruiting in New Britain — not just this study.

Browse ALS Trials in New Britain →

Browse More Trials by Condition

ALS TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in New Britain?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Britain, CT